Antibodies and Peptides: Pioneering Drug Discovery for COVID-19

Monday, 14 October 2024, 06:47

Antibodies and peptides are crucial in drug discovery for COVID-19. Using biomimicry, companies are exploring novel therapeutic candidates derived from nature. This article delves into five innovative biotech firms that leverage biological wisdom to combat the pandemic.

Labiotech — Antibodies and Peptides: Pioneering Drug Discovery for COVID-19

Introduction to Antibodies and Drug Discovery

Antibodies are vital in addressing COVID-19, especially through drug discovery techniques using peptides. Peptides derived from natural sources are being explored for their therapeutic potential against various diseases, including COVID-19.

Biomimicry in Action

Biotech firms are turning to nature for inspiration. Here, we examine five companies developing breakthroughs through biomimicry, enhancing our abilities to fight infectious diseases like COVID-19.

1. Celtic Biotech

Leading Drug: CB-24 for Cancer
Biological Source: Snake venom for therapeutic development.

2. ExeVir

Leading Drug: XVR011 for COVID-19
Therapeutic Approach: Llama-derived nanobodies targeting virus variants.

3. Fauna Bio

Focus: Genetic data for drug discovery.
AI Usage: Uncovering survival patterns across species.

4. Isogenica

Specialization: Small-format antibodies for diverse therapies.

5. Soricimed

Leading Drug: SOR-C13 for Cancer
Discovery: Peptides from shrew saliva targeted at solid tumors.

The Future of Biomimicry in Drug Discovery

Biomimicry represents a promising frontier in drug discovery, especially with the ongoing need for effective COVID-19 treatments. As research expands, more firms will likely adopt this innovative approach to uncover next-generation therapeutics.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.